BRIEF-Novelis Inc Says Plans To Withdraw IPO- SEC Filing-August 2024-www.financetom.com

BRIEF-Novelis Inc Says Plans To Withdraw IPO- SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Novelis Inc Says Plans To Withdraw IPO- SEC Filing

Oct 10, 2024 9:39 PM

Oct 8 (Reuters) - Novelis Inc:

* NOVELIS INC - PLANS TO WITHDRAW IPO- SEC FILING

Source text for Eikon:

Further company coverage:

Previous page： Krystal Biotech Q2 Earnings, Revenue Rise Next page： BioNTech Q2 Loss Narrows, Revenue Increases; Reaffirms 2025 Revenue Guidance

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Krystal Biotech Q2 Earnings, Revenue Rise

Aug 4, 2025

07:17 AM EDT, 08/04/2025 (MT Newswires) -- Krystal Biotech ( KRYS ) reported Q2 earnings Monday of $1.29 per diluted share, up from $0.53 a year earlier. Two analysts polled by FactSet expected $1. Net product revenue for the quarter ended June 30 was $96 million, compared with $70.3 million a year earlier. Analysts surveyed by FactSet expected $92 million....

BioNTech Q2 Loss Narrows, Revenue Increases; Reaffirms 2025 Revenue Guidance

Aug 4, 2025

07:17 AM EDT, 08/04/2025 (MT Newswires) -- BioNTech (BNTX) reported a Q2 loss Monday of 1.60 euros ($1.85) per share, narrowing from a loss of 3.36 euros a year earlier. Analysts polled by FactSet expected a loss of 2.28 euros per share. Revenue for the quarter ended June 30 was 260.8 million euros, up from 128.7 million euros a year...

TG Therapeutics Q2 Earnings, Revenue Rise

Aug 4, 2025

07:22 AM EDT, 08/04/2025 (MT Newswires) -- TG Therapeutics ( TGTX ) reported Q2 net income Monday of $0.17 per diluted share, up from $0.04 a year earlier. Analysts polled by FactSet expected $0.21. Revenue for the quarter ended June 30 was $141.1 million, compared with $73.5 million a year earlier. Analysts surveyed by FactSet expected $138 million. For 2025,...

Axsome Therapeutics Q2 Net Loss Narrows, Revenue Increases

Aug 4, 2025

07:21 AM EDT, 08/04/2025 (MT Newswires) -- Axsome Therapeutics ( AXSM ) reported a Q2 net loss Monday of $0.97 per diluted share, compared with a loss of $1.67 a year earlier. Analysts polled by FactSet expected a loss of $1.13. Total revenue for the quarter ended June 30 was $150 million, up from $87.2 million a year earlier. Analysts...